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OBJECTIVES To test the hypothesis that interleukin-1 receptor antagonist (IL-1ra) gene polymorphism
contributes to the risk of restenosis after coronary stenting.
BACKGROUND Cytokines of the interleukin-1 (IL-1) family play a central role in regulating inflammatory
responses. There is strong evidence to support IL-1 involvement in smooth muscle cell
mitogenesis and extracellular matrix metabolism. The IL-1ra counters the proinflammatory
effects of IL-1. The interleukin-1 receptor antagonist gene (IL-1RN) contains several
well-characterized polymorphic sites that correlate with altered IL-1ra levels.
METHODS In 1,850 consecutive patients, clinical and angiographic measures of restenosis were evaluated
over one year after coronary stent placement. Repeat angiography at six months was achieved
in 84% of the patients; angiographic restenosis was defined #50% diameter stenosis at
follow-up. Genotyping for an exon 2 polymorphism (12,018) of IL-1RN (alleles 1 and 2)
was based on a polymerase chain reaction technique.
RESULTS Allele 2 frequency was 0.28. Carriers of allele 2 had a significantly lower risk for angiographic
restenosis, odds ratio (OR) of 0.78 (95% confidence interval, 0.63 to 0.97) and target vessel
revascularization, OR of 0.73 (0.58 to 0.92) compared with noncarriers. Risk reduction was
especially significant in patients ,60 years (n 5 696), with OR of 0.63 (0.43 to 0.91) for
angiographic restenosis and 0.55 (0.39 to 0.78) for target vessel revascularization.
CONCLUSIONS Allele 2 of the IL-1ra gene was associated with a lower incidence of restenosis after coronary
stenting, particularly in younger patients. This finding supports a role of inflammation in the
development of restenosis after stent placement. (J Am Coll Cardiol 2000;36:2168–73) ©
2000 by the American College of Cardiology
There is increasing evidence for an important role of
inflammation in coronary artery disease (1). Cytokines of
the interleukin-1 (IL-1) family are central regulators in
immunoinflammatory mechanisms (2), and intensive work
has been focused on IL-1 modifiers that may influence the
inflammatory response (3). Data from several studies sup-
port IL-1 regulation of endothelial and smooth muscle cell
mitogenesis, thrombogenic response of endothelial cells,
leukocyte adherence, lipoprotein metabolism, extracellular
matrix production and vascular permeability (4,5). With
these actions, IL-1 occupies a key place in the cascade of
autocrine and paracrine mediators that promote restenosis
after percutaneous coronary interventions (6).
Restenosis remains a significant limitation for stenting,
affecting around 30% of patients treated with this proce-
dure. It is assumed to be the result of a particularly high
degree of arterial injury and inflammatory reaction produced
by the stent (7). Due to the potent proinflammatory actions
of IL-1, the regulation of IL-1 activity by endogenous
biological antagonists may play a significant role in this
process. Of particular interest is the naturally occurring IL-1
receptor antagonist (IL-1ra) (8), which is the product of a
polymorphic gene (IL-1 receptor antagonist gene [IL-
1RN]). Five polymorphic sites have been discovered in the
IL-1RN: a variable number tandem repeat (VNTR) poly-
morphism in intron 2, and four single nucleotide polymor-
phisms, including one in exon 2, that show a high degree of
linkage disequilibrium with the VNTR (9). These IL-1RN
polymorphisms have been associated with altered produc-
tion rates of IL-1ra protein (10–12). In view of the central
role of IL-1 in regulation of the inflammatory response and
the potent inhibitory effect of IL-1ra in this system, the
hypothesis that the IL-1RN locus may contribute genetic
risk in inflammatory diseases was proposed (2,13). In recent
years this hypothesis has been extensively tested, and sig-
nificant associations have been found between IL-1RN
polymorphism and inflammatory diseases (13). More re-
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cently, this polymorphism has been found to be associated
with single-vessel coronary artery disease in younger pa-
tients (14).
The objective of this study was to test for association
between IL-1ra gene polymorphism and risk for restenosis
after coronary stent placement in a large cohort of patients.
METHODS
Patients. The study included 1,850 consecutive Caucasian
patients with symptomatic coronary artery disease who
underwent coronary stent implantation at our institutions
during the period between January 1996 and June 1997. All
patients were scheduled for angiographic follow-up at 6
months; they gave written informed consent for the inter-
vention, follow-up angiography and genotype determina-
tion. The study protocol conformed to the Declaration of
Helsinki and was approved by the institutional ethics
committee at our institution. Adjunct pharmacologic ther-
apy consisted of aspirin (100 mg twice daily, indefinitely)
and ticlopidine (250 mg twice daily for four weeks). Patients
considered at a higher risk for stent thrombosis received
adjunct therapy with the glycoprotein-IIb/IIIa blocker ab-
ciximab given as bolus injection during stent insertion
procedure and as a 12-h continuous infusion thereafter.
Determination of the IL-1RN genotype. Genomic DNA
was extracted from 200 ml of peripheral blood leukocytes
with the QIAamp Blood Kit (Qiagen, Hilden, Germany)
and the High Pure PCR Template Preparation Kit (Boehr-
inger Mannheim, Mannheim, Germany).
Interleukin-1 receptor antagonist gene genotyping was
performed with the ABI Prism Sequence Detection System
(PE Applied Biosystems, Weiterstadt, Germany). The IL-
1RN (12,018), a single base pair polymorphism in exon 2,
was the polymorphism typed in this study (9). The nucle-
otide sequences of primers and probes were as follows:
forward primer 59 GGG ATG TTA ACC AGA AGA
CCT TCT ATC T 39, reverse primer 59 CAA CCA CTC
ACC TTC TAA ATT GAC ATT 39, allele 1 probe 59
AAC AAC CAA CTA GTT GCT GGA TAC TTG
CAA 39, allele 2 probe 59 ACA ACC AAC TAG TTG
CCG GAT ACT TGC 39. Genotype validation was
performed by repeating the determination in 20% of the
patients using a duplicate DNA sample with a novel subject
code unrelated to the original subject code. There was a
100% matching between the two results.
Angiographic assessment. Quantitative computer-assisted
angiographic analysis was performed off-line using the
automated edge-detection system CMS (Medis Medical
Imaging Systems, Nuenen, the Netherlands). Operators
were unaware of the patient’s IL-1RN genotype. Acute
lumen gain was calculated as the difference between mini-
mal lumen diameter (MLD) at the end of intervention and
MLD before the intervention. Late lumen loss was calcu-
lated as the difference between MLD at the end of inter-
vention and MLD at the time of follow-up angiography.
Loss index was calculated as the ratio between late lumen
loss and acute lumen gain.
Definitions and study end points. The primary end point
of the study was restenosis. Two definitions of restenosis
were assessed: the incidence of a diameter stenosis of $50%
at six-month follow-up angiography and the need for target
vessel revascularization (TVR) (percutaneous transluminal
coronary angioplasty [PTCA] or bypass surgery) due to
symptoms or signs of ischemia in the presence of angio-
graphic restenosis at the stented site over one year after stent
placement. Other major adverse events evaluated were death
from any cause and nonfatal myocardial infarction (MI).
The diagnosis of acute MI was based on the presence of new
pathological Q waves or a value of creatine kinase or its MB
isoenzyme at least 3 times the upper limit (15). Clinical
events were assessed on the basis of the information pro-
vided by hospital readmission records, referring physician or
phone interview with the patient. For all patients who
presented cardiac symptoms during the interview, at least
one clinical and electrocardiographic evaluation was per-
formed at the outpatient clinic or by the referring physician.
Statistical analysis. Discrete variables are expressed as
counts or percentages and compared with the chi-square or
Fisher exact test, as appropriate. Continuous variables are
expressed as mean 6 standard deviation and compared by
means of the unpaired, two-sided t-test or analysis of
variance for more than two groups. Risk analysis was
performed calculating the odds ratio (OR) and the 95%
confidence interval (CI). The main analysis consisted in
comparing combined heterozygous and homozygous carri-
ers of the IL-1RN*2 allele with homozygous carriers of the
IL-1RN*1 allele. A multivariate logistic regression model
was applied to adjust for those clinical and lesion-related
characteristics for which the comparison between carriers
and noncarriers of the IL-1RN*2 allele yielded a p value
#0.30. Since the relative contribution of genetic factors to
multifactorial processes such as restenosis may decrease with
the age, we carried out an additional prespecified subgroup
analysis of patients ,60 years. Successively, we used a test
for trend for assessing gene dose effect, i.e. a stepwise
increasing or decreasing phenotypic response with the
presence of 0, 1 or 2 putative alleles. Statistical significance
was accepted for p values ,0.05.
Abbreviations and Acronyms
CI 5 confidence interval
IL-1 5 interleukin-1
IL-1ra 5 interleukin-1 receptor antagonist
IL-1RN 5 interleukin-1 receptor antagonist gene
MI 5 myocardial infarction
MLD 5 minimal lumen diameter
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary
angioplasty
TVR 5 target vessel revascularization
VNTR 5 variable number tandem repeat
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RESULTS
Patients characteristics. The observed IL-1RN genotypes
in the study population were 1/1 in 954 (51.6%), 1/2 in 742
(40.1%) and 2/2 in 154 (8.3%). Thus, the frequency for the
allele 2 was 0.28. Main baseline characteristics of the
patients are listed in Table 1. There was only a trend toward
a higher frequency of diabetes among carriers of the IL-
1RN*2 allele. The angiographic and procedural character-
istics at the time of intervention are listed in Table 2 and
show no significant differences between carriers and non-
carriers of the IL-1RN*2 allele.
IL-1RN polymorphism, mortality and MI after stenting.
Table 3 shows similar adverse clinical event rates in carriers
and noncarriers of the IL-1RN*2 allele during the first 30
days after coronary stenting. However, this study was not
sufficiently powered to assess the potential influence of the
IL-1ra gene polymorphism on 30-day events.
One-year follow-up (complete in 98.4% of the patients)
also indicated that there was no correlation between the
presence of the IL-1RN*2 allele and mortality or incidence
of MI after the intervention. The graph in the left panel of
Figure 1 displays the OR for these events associated with
the presence of the IL-1RN*2 allele. During the one-year
period, the mortality rate was 2.8% in the combined group
of IL-1RN 1/2 and IL-1RN 2/2 patients and 2.2% in IL-1
1/1 patients (p 5 0.42). The incidence of nonfatal MI was
3.5% in IL-1RN*2 allele carriers and 3.9% in homozygous
carriers of the IL-1RN*1 allele (p 5 0.54).
IL-1RN polymorphism and restenosis after stenting.
Six-month follow-up angiography was performed in 84% of
the patients, in a similar proportion among carriers and
noncarriers of the IL-1RN*2 allele. Table 4 lists the results
of the quantitative assessment of six-month angiograms.
The presence of the IL-1RN*2 allele was associated with a
22% decrease in the risk for restenosis, OR 0.78 (95% CI,
0.63 to 0.97; Fig. 1). More specifically, the restenosis rate
was 35.6% in IL-1RN 1/1, 30.4% in IL-1RN 1/2 and
29.1% in IL-1RN 2/2 patients (p 5 0.03, test for trend).
Clinical restenosis requiring TVR was also significantly
lower, 17.7% in IL-1RN*2 allele carriers versus 22.7% in
homozygous patients for the IL-1RN*1 allele (p 5 0.03),
yielding an OR of 0.73 (0.58 to 0.92), as shown in Figure 1.
Target vessel revascularization rates were 22.7% in IL-1RN
1/1, 18.3% in IL-1RN 1/2 and 14.9% in IL-1RN 2/2
patients (p 5 0.005, test for trend).
Multivariate analysis of the correlates of angiographic
Table 1. Baseline Clinical Characteristics
IL-1RN 1/2
or 2/2
(n 5 896)
IL-1RN
1/1
(n 5 954)
p
Value
Age, yr 63.4 6 10.0 62.6 6 10.0 0.11
Women, % 22.4 19.9 0.19
Arterial hypertension, % 67.2 68.9 0.44
Diabetes, % 22.7 19.4 0.08
Current or former smoker, % 38.7 41.2 0.28
Elevated total cholesterol, % 42.5 43.1 0.81
Acute myocardial infarction, % 20.3 20.2 0.97
Unstable angina, % 27.9 27.8 0.95
Prior bypass surgery, % 10.6 11.5 0.53
Number of diseased coronary vessels 0.39
1 vessel, % 29.2 27.3
2 vessels, % 32.9 31.9
3 vessels, % 37.8 40.9
Data are proportions or mean 6 standard deviation.
Table 2. Lesion and Procedural Characteristics at the Time
of Intervention
IL-1RN 1/2
or 2/2
(n 5 896)
IL-1RN
1/1
(n 5 954)
p
Value
Target coronary vessels 0.89
Left main, % 1.3 1.6
LAD, % 40.1 39.3
LCx, % 19.9 20.0
RCA, % 32.6 31.9
Venous bypass graft, % 6.1 7.2
Complex lesions, % 75.2 74.1 0.58
Restenotic lesions, % 25.3 23.3 0.30
Before stenting
Reference diameter, mm 3.02 6 0.53 3.05 6 0.54 0.29
Diameter stenosis, % 79.1 6 14.9 78.7 6 15.7 0.57
Lesion length, mm 12.1 6 6.9 12.1 6 6.6 0.98
Procedural data
Measured balloon diameter, mm 3.2 6 0.5 3.2 6 0.5 0.45
Maximal balloon pressure, atm 13.9 6 3.3 13.8 6 3.2 0.20
Stent type: 0.89
Inflow*, % 33.5 34.3
JOSTENT†, % 5.6 6.5
MULTI-LINK‡, % 5.8 6.6
NIR§, % 13.1 12.5
Palmaz-Schatz\, % 15.6 15.5
PURA-A¶, % 20.1 18.0
other, % 6.4 6.6
Stented segment length, mm 20.0 6 14.3 20.3 6 13.6 0.70
Periprocedural abciximab
therapy, %
19.8 19.6 0.93
Immediately after stenting
Diameter stenosis, % 5.2 6 9.1 5.4 6 7.6 0.47
*Inflow Dynamics, Munich, Germany; †JOMED International AB, Helsingborg,
Sweden; ‡Guidant, Advanced Cardiovascular Systems, Santa Clara, California;
§Scimed, Boston Scientific Europe, Verviers, Belgium; \Johnson & Johnson Inter-
national Systems, Warren, New Jersey; ¶Devon Medical, Hamburg, Germany.
Data are proportions or mean 6 standard deviation.
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; RCA 5 right coronary artery; complex lesions were defined as ACC/AHA
lesion types B2 and C, according to the American College of Cardiology/American
Heart Association grading system.
Table 3. Incidence of Adverse Events Recorded During the
Early 30 Days
IL-1RN
1/2 or 2/2
(n 5 896)
IL-1RN
1/1
(n 5 954)
p
Value
Death, % 0.9 0.9 0.91
Nonfatal myocardial infarction, % 3.3 2.6 0.52
Q wave, % 1.1 0.7 0.39
non-Q wave, % 2.2 1.9 0.60
Target vessel revascularization, % 3.0 2.3 0.34
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restenosis was performed with the variables age, gender,
diabetes, smoking, restenotic lesions and vessel size (all
variables differing in univariate analysis by a p value #0.30)
along with the presence or absence of the IL-1RN*2 allele.
The presence of the IL-1RN*2 allele was independently
(p , 0.001) correlated with a decreased risk for restenosis
with an adjusted OR of 0.81 (0.71 to 0.92). In addition,
there was a significant interaction between the presence of
the IL-1RN*2 allele and age (p 5 0.009) as reflected by a
progressively stronger protective effect of this allele in
younger patients.
The results of the analysis in the prespecified subgroup of
patients ,60 years (n 5 696) are presented in Table 5,
Figure 1 and Figure 2. The frequency for the allele 2 among
these patients was 0.27, and there were no significant
differences in baseline characteristics between allele 2 carri-
ers and homozygous patients for allele 1. During the
one-year follow-up period, 17.1% of the IL-1RN*2 allele
carriers and 24.9% of the homozygous IL-1RN*1 allele
carriers needed TVR (p 5 0.01). Thus, the presence of the
IL-1RN*2 allele was associated with a 37% risk reduction
(OR, 0.63 [0.43 to 0.91], Fig. 1) of the need of reinterven-
tions. Quantitative data obtained for six-month angiogra-
phy (performed in 590 or 85% of patients ,60 years) are
displayed in Table 5. The incidence of angiographic resten-
osis was 25.6% in the combined group of IL-1RN 1/2 and
IL-1RN 2/2 patients and 38.5% among IL-1RN 1/1
patients (p , 0.001), which corresponds to a 45% risk
reduction (OR, 0.55 [0.39 to 0.78], Fig. 1). Figure 2
illustrates the gene dose effect verified in the subgroup of
younger patients. The incidence of restenosis decreased
progressively with heterozygosity and homozygosity for the
IL-1RN*2 allele. The rate of angiographic restenosis was
38.5% in IL-1RN 1/1 patients, 26.3% in IL-1RN 1/2
patients and 22.4% in IL-1RN 2/2 patients (p 5 0.001, test
for trend; Fig. 2). Target vessel revascularization rates were
24.9% in IL-1RN 1/1 patients, 17.9% in IL-1RN 1/2
patients and 13.2% in IL-1RN 2/2 patients (p 5 0.01, test
for trend; Fig. 2).
DISCUSSION
Restenosis remains the major limitation of coronary stent-
ing and other percutaneous interventions. Restenosis is not
a random phenomenon, and certain patients are at increased
risk of developing it (16). There are several clinical and
lesion-related factors that serve to explain part of the risk for
restenosis (17). However, a significant portion of this
process can not be predicted based on conventional risk
factors (18). Recent studies have provided evidence on the
emerging role of genetic factors in determining the risk for
restenosis after coronary interventions (19).
In this study we assessed the association between a
polymorphism in the gene encoding IL-1ra and both
angiographic and clinical restenosis after coronary stent
implantation in a large and consecutive series of patients
with systematic angiographic control study at 6 months
achieved in a very high proportion of patients. The rationale
for choosing IL-1RN as a candidate gene in restenosis after
coronary stenting came from the evidence of the role of
Table 4. Results at Follow-up Angiography
IL-1RN 1/2 or 2/2
(n 5 758)
IL-1RN 1/1
(n 5 798)
p
Value
Late lumen loss, mm 1.16 6 0.82 1.24 6 0.86 0.07
Loss index 0.53 6 0.38 0.59 6 0.45 0.009
Diameter stenosis, % 41.8 6 26.2 45.2 6 28.7 0.02
Restenosis rate, % 30.2 35.6 0.02
Data are proportions or mean 6 standard deviation.
Table 5. Results at Follow-up Angiography in Patients
,60 Years
IL-1RN 1/2 or 2/2
(n 5 273)
IL-1RN 1/1
(n 5 317)
p
Value
Late lumen loss, mm 1.08 6 0.77 1.27 6 0.93 0.008
Loss index 0.49 6 0.35 0.59 6 0.48 0.003
Diameter stenosis, % 39.3 6 24.1 46.7 6 30.5 0.001
Restenosis rate, % 25.6 38.5 ,0.001
Data are proportions or mean 6 standard deviation.
Figure 1. Graph showing on a logarithmic scale the odds ratios for clinical events and angiographic restenosis associated with the presence of the IL-1RN*2
allele for the entire population (left panel) and patients ,60 years (right panel). ILRN 5 interleukin-1 receptor antagonist gene; MI 5 myocardial
infarction; TVR 5 target vessel revascularization.
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inflammation in this process, the central role of the IL-1
system in inflammatory regulation, the previous evidence of
IL-1RN polymorphism as a genetic risk factor in other
inflammatory diseases and the therapeutic prospects offered
by IL-1 antagonist approaches.
Previous evidence on the relation between IL-1 family
and restenosis. Interleukin-1 is a key mediator of immu-
noinflammatory responses and is considered to be extraor-
dinarily potent since a very low level of binding to the
signaling (type I) IL-1 receptor is sufficient to elicit a full
response (5). Interleukin-1 has been established as a signif-
icant determinant of intimal hyperplasia and has been
demonstrated to stimulate the thrombogenic response in
endothelial cells as well as the production of endothelial-
derived growth factor (4). Coronary angioplasty evokes
marked monocyte activation (20). The capacity of in vitro-
stimulated monocytes to produce IL-1 has been demon-
strated to correlate with lumen renarrowing after PTCA
(21). In an IL-1RN knockout mouse model, extensive
inflammatory cell infiltrate, which is characteristic of the
restenotic response, was observed in the aorta and its major
branches, including the coronary arteries (22). In addition,
the use of recombinant human IL-1ra inhibited vascular
smooth muscle cell proliferation in cell cultures (23).
IL-1ra gene polymorphism and restenosis after stenting.
In this study, which included 1,850 consecutive patients
with coronary stent implantation, we found that the pres-
ence of allele 2 in the IL-1ra gene was significantly
associated with a lower risk of both angiographic and
clinical restenosis. This association was even stronger in
younger patients. A clear gene dose effect was found; the
incidence of restenosis decreased with heterozygosity and
even more so with homozygosity for the IL-1RN*2 allele.
The presence of allele 2 has been shown to be associated
with higher blood levels or higher monocyte production
rates of IL-1ra (10–12) but not in all populations (12) and
not when measured as IL-1RN RNA (9). Interleukin-1
receptor antagonist production increases with age (24) and
this may explain, at least in part, the more powerful genetic
association in younger patients. In terms of biological
function, however, the genotype associated with restenosis
in this study cannot yet be confidently defined as specifying
a high or low IL-1 production phenotype because gene
activation patterns are often tissue specific. It is not possible
to extrapolate from studies on blood levels or in vitro
monocyte production the effect of genotype on concentra-
tion of IL-1ra at coronary artery sites after stenting. In
addition, as with other clinical studies on genetic associa-
tions, the data presented here do not provide evidence for a
causal role of the IL-1RN polymorphism in the complex
process of restenosis after coronary stenting. Interleukin-1
receptor antagonist gene lies on a 430kB stretch of chro-
mosome 2 (25), and there is a strong haplotype effect in the
region (26), so unknown genes may well be in linkage
disequilibrium with IL-1RN. In this case the IL-1RN
polymorphism would be serving as a marker for an unknown
etiological gene. We cannot claim more than this based on
presently available data. However, as described above, there
is a biological rationale for IL-1 as a mediator of arterial
disease and, therefore, a role for IL-1RN.
Study limitations. Despite the tissue specificity of IL-1ra
gene activation patterns discussed above, the lack of mea-
surements of blood levels or monocyte production of IL-1ra
should be considered a limitation because they might have
provided some mechanistic insights into the association
observed in this study. A second limitation to acknowledge
is the incomplete six-month angiographic follow-up
(present in only 84% of the patients), which may inadver-
tently have introduced a bias in our angiographic restenosis
analysis. However, this bias is not expected to be relevant
given the concordance between the angiographic and clin-
ical measures of restenosis.
Conclusions. The results of this study showed a significant
association between IL-1RN polymorphism and restenosis
after coronary stenting and that IL-1RN*2 carriage has a
protective effect, especially in patients ,60 of age. For
reasons given above, the biological mechanism underlying
this genetic finding is, at present, difficult to define in the
current state of knowledge. The finding does, however, lend
support to the hypothesis that genetic programming of the
inflammatory response may be relevant to the pathogenesis
of restenosis after stenting. The finding may provide not
only a genetic marker for risk stratification but also the
rationale for the assessment of the value of IL-1 antagonists
as a preventive strategy against restenosis.
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Figure 2. Bar graph showing the decrease in the incidence of restenosis and
TVR in patients ,60 years with the increase in the number of IL-1RN*2
alleles. ILRN 5 interleukin-1 receptor antagonist gene; TVR 5 target
vessel revascularization.
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